WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Donald Santel as a member of Aerovate’s Board of Directors. With over 40 […]
Tag: Aerovate
Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research
Phase 1 results showed that AV-101 was generally well tolerated with significantly reduced systemic exposure compared to oral imatinib in healthy adult participants WALTHAM, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of […]
Aerovate Therapeutics Announces Third Quarter 2022 Financial Results
WALTHAM, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter ended September 30, 2022, and recent business highlights. Recent Highlights Progress Continued […]
Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension
WALTHAM, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary diseases, today announced the initiation of its Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) Phase 2b/Phase 3 trial to evaluate the safety and efficacy […]
Aerovate Therapeutics Announces Third Quarter 2021 Financial Results
WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced our financial results for the quarter ended September 30, 2021, and recent events. “We continue to make […]
Aerovate Therapeutics Announces Second Quarter 2021 Financial Results
WALTHAM, Mass. , Aug. 16, 2021 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced its financial results for the quarter ended June 30, 2021, and recent events. “It has […]
Aerovate Therapeutics Announces Pricing of Upsized Initial Public Offering
BOSTON, June 29, 2021 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the pricing of its upsized initial public offering of 8,682,142 shares of common stock at a […]
Recent
MicroTransponder Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation
New Minimally Invasive Therapy at MemorialCare Heart & Vascular Institute Reduces Cardiovascular Mortality by Nearly 30% in Patients with Resistant Hypertension
Zylox-Tonbridge to Acquire Equity Interest in A European Medical Device Company to Accelerate Expansion in the Global MedTech Market
Popular
- No commented posts yet